Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Stock Information for Galmed Pharmaceuticals Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Galmed Pharmaceuticals Ltd.

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Galmed Issues CEO Letter to Shareholders
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.